New version released of aPROMISE

New version released of aPROMISE

We have now released a new version of aPROMISE for prostate cancer analysis. The new version include features such as: Parallel Study Review Select all suggested hotspots CT Measurement Tool Configurable Crosshair User Specific Settings Report Improvements...

EXINI Diagnostics AB, a Lantheus company (EXINI), announced today a ‘License and Development’ agreement with Curium, a world leader in nuclear medicine , to customize EXINI’s artificial intelligence (AI) platform for use in Europe.

Under the terms of the agreement, EXINI’s deep learning platform will be tailored to meet the specific needs of the European market. The clinical value proposition of the platform is to increase the efficiency and reproducibility of PSMA PET/CT image assessments in...